Fibroblast activation protein peptide-targeted NIR-I/II fluorescence imaging for stable and functional detection of hepatocellular carcinoma
- PMID: 39836214
- DOI: 10.1007/s00259-025-07093-6
Fibroblast activation protein peptide-targeted NIR-I/II fluorescence imaging for stable and functional detection of hepatocellular carcinoma
Abstract
Purpose: Cancer-associated fibroblasts (CAFs) are the primary stromal component of the tumor microenvironment in hepatocellular carcinoma (HCC), affecting tumor progression and post-resection recurrence. Fibroblast activation protein (FAP) is a key biomarker of CAFs. However, there is limited evidence on using FAP as a target in near-infrared (NIR) fluorescence imaging for HCC. Thus, this study aims to develop a novel NIR fluorescent imaging strategy targeting FAP+ CAFs in HCC.
Methods: The ICG-FAP-TATA probe was synthesized by conjugating a novel cyclization anti-FAP peptide with an indocyanine green derivative (ICG-NH2) as fluorophore, capable for NIR window I (NIR-I, 700-900 nm) and II (NIR-II, 1000-1700 nm) imaging. Its efficacy in lesion localization and other potential applications was evaluated.
Results: In vivo imaging of subcutaneous HCC models revealed that ICG-FAP-TATA specifically targeted FAP+ CAFs in the stroma and detected differences in CAFs loading within lesions. The fluorescence intensity/tumor-to-background ratio (TBR) positively correlated with FAP expression (R2 > 0.8, p < 0.05). Ex vivo incubation of tumor tissues with ICG-FAP-TATA provided stable fluorescence imaging of tumors in subcutaneous and orthotopic HCC models, including different cell line co-culture systems (LM3-luc, MHCC97H-luc, HepG2-luc + LX2), and various liver backgrounds (healthy/fibrotic) (n = 5 per group). TBR of the tumor mice models was higher for NIR-II than NIR-I imaging (3.89 ± 1.27 vs. 2.64 ± 0.64, p < 0.05). Moreover, NIR-I/II imaging of fresh tissues from seven patients with HCC undergoing surgery incubated with ICG-FAP-TATA visually provided the spatial distribution heterogeneity of CAFs. The targeted fluorescence was relatively enriched more in the blood flow direction and at the tumor edge, both of which were associated with tumor metastasis (all p < 0.05).
Conclusion: This study presents a rapid and effective method for detecting HCC lesions, locating FAP+ CAFs, and visualizing high-risk areas for tumor metastasis at the macroscopic level. It offers a new promising approach with translational potential for imaging HCC.
Keywords: Cancer-associated fibroblasts; Fibroblast activation protein; Hepatocellular carcinoma; Near-infrared fluorescence; Peptide-targeted fluorescence imaging.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval: This study, approved by the Fifth Affiliated Hospital of Sun Yat-sen University Medical Ethical Review (Ethics No. L002-1), obtained informed consent from all participants. Animal experiments followed the principles of the Declaration of Helsinki and were supervised by the Laboratory Animal Ethics Committee of the Institute of Automation, Chinese Academy of Sciences (Ethics No. IA21-2302-420303). Competing interests: The authors have no relevant financial or non-financial interests to disclose.
Similar articles
-
Rational Design and Synthesis of Peptide-Based Probes for Fibroblast Activation Protein-Targeted Magnetic Resonance and NIR-I/II Fluorescence Imaging of Cancer-Associated Fibroblasts.Anal Chem. 2025 Jul 22;97(28):15072-15084. doi: 10.1021/acs.analchem.5c00951. Epub 2025 Jul 14. Anal Chem. 2025. PMID: 40653873
-
NIR-II fluorescence-guided liver cancer surgery by a small molecular HDAC6 targeting probe.EBioMedicine. 2023 Dec;98:104880. doi: 10.1016/j.ebiom.2023.104880. Epub 2023 Nov 29. EBioMedicine. 2023. PMID: 38035463 Free PMC article.
-
Near-Infrared II Fluorescence Imaging Highlights Tumor Angiogenesis in Hepatocellular Carcinoma with a VEGFR-Targeted Probe.Small Methods. 2025 Mar;9(3):e2400904. doi: 10.1002/smtd.202400904. Epub 2024 Oct 21. Small Methods. 2025. PMID: 39428866
-
The application of the fibroblast activation protein α-targeted immunotherapy strategy.Oncotarget. 2016 May 31;7(22):33472-82. doi: 10.18632/oncotarget.8098. Oncotarget. 2016. PMID: 26985769 Free PMC article. Review.
-
Research progress on the role of fibroblast activation protein in diagnosis and treatment of cancer.Nucl Med Commun. 2022 Jul 1;43(7):746-755. doi: 10.1097/MNM.0000000000001565. Epub 2022 May 4. Nucl Med Commun. 2022. PMID: 35506275 Review.
Cited by
-
Preclinical and pilot clinical evaluation of novel dual-modality pet/fluorescence probes targeting FAP for accurate tumor margin delineation.Eur J Nucl Med Mol Imaging. 2025 Aug 23. doi: 10.1007/s00259-025-07512-8. Online ahead of print. Eur J Nucl Med Mol Imaging. 2025. PMID: 40848055
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. https://doi.org/10.3322/caac.21708.
-
- Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345–62. https://doi.org/10.1016/s0140-6736(22)01200-4.
-
- Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18:792–804. https://doi.org/10.1038/s41571-021-00546-5.
-
- Cogliati B, Yashaswini CN, Wang S, Sia D, Friedman SL. Friend or foe? The elusive role of hepatic stellate cells in liver cancer. Nat Rev Gastroenterol Hepatol. 2023;20:647–61. https://doi.org/10.1038/s41575-023-00821-z.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous